{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:21:44Z","timestamp":1762078904449,"version":"3.44.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.amjmed.2007.01.005","type":"journal-article","created":{"date-parts":[[2007,2,22]],"date-time":"2007-02-22T09:27:24Z","timestamp":1172136444000},"page":"S26-S34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"S1","title":["Therapeutic Options for Modifying Cardiometabolic Risk Factors"],"prefix":"10.1016","volume":"120","author":[{"given":"Louis J.","family":"Aronne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2007.01.005_bib1","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.295.13.1549","article-title":"Prevalence of overweight and obesity in the United States, 1999\u20132004","volume":"295","author":"Ogden","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2007.01.005_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1385\/ENDO:29:1:109","article-title":"Epidemiology, trends, and morbidities of obesity and the metabolic syndrome","volume":"29","author":"Bray","year":"2006","journal-title":"Endocrine"},{"key":"10.1016\/j.amjmed.2007.01.005_bib3","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/01.ATV.0000216787.85457.f3","article-title":"Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss","volume":"26","author":"Poirier","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"year":"2000","series-title":"The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults","key":"10.1016\/j.amjmed.2007.01.005_bib4"},{"key":"10.1016\/j.amjmed.2007.01.005_bib5","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJMra012586","article-title":"Obesity","volume":"346","author":"Yanovski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2007.01.005_bib6","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2007.01.005_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2007.01.005_bib8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.7326\/0003-4819-142-8-200504190-00009","article-title":"The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program Randomized Trial","volume":"142","author":"Orchard","year":"2005","journal-title":"Ann Intern Med"},{"issue":"suppl 4","key":"10.1016\/j.amjmed.2007.01.005_bib9","first-page":"553S","article-title":"Sibutramine: a novel new agent for obesity treatment","volume":"3","author":"Ryan","year":"1995","journal-title":"Obes Res"},{"key":"10.1016\/j.amjmed.2007.01.005_bib10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0278-5846(88)90003-6","article-title":"The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation","volume":"12","author":"Buckett","year":"1988","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"suppl 4","key":"10.1016\/j.amjmed.2007.01.005_bib11","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.ijo.0801930","article-title":"When, for whom and how to use sibutramine?","volume":"25","author":"Astrup","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.amjmed.2007.01.005_bib12","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomized trial","volume":"356","author":"James","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2007.01.005_bib13","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","article-title":"Randomized trial of lifestyle modification and pharmacotherapy for obesity","volume":"353","author":"Wadden","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2007.01.005_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial","volume":"281","author":"Davidson","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2007.01.005_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients","volume":"352","author":"Sjostrom","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2007.01.005_bib16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/archfami.9.2.160","article-title":"Orlistat in the long-term treatment of obesity in primary care settings","volume":"9","author":"Hauptman","year":"2000","journal-title":"Arch Fam Med"},{"key":"10.1016\/j.amjmed.2007.01.005_bib17","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1053\/meta.2001.28078","article-title":"Beneficial effects of metformin in normoglycemic morbidly obese adolescents","volume":"50","author":"Kay","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.amjmed.2007.01.005_bib18","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjmed.2007.01.005_bib19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/oby.2004.76","article-title":"Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients","volume":"12","author":"Hollander","year":"2004","journal-title":"Obes Res"},{"key":"10.1016\/j.amjmed.2007.01.005_bib20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience for the RIO-Europe study","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2007.01.005_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002130050953","article-title":"Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors","volume":"143","author":"Williams","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.amjmed.2007.01.005_bib22","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/sj.bjp.0704767","article-title":"Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol","volume":"136","author":"Kirkham","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.amjmed.2007.01.005_bib23","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.2337\/diabetes.54.10.2838","article-title":"Activation of the peripheral endocannabinoid system in human obesity","volume":"54","author":"Engeli","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.amjmed.2007.01.005_bib24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO\u2013North America: a randomized controlled trial","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2007.01.005_bib25","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","article-title":"Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study","volume":"368","author":"Scheen","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2007.01.005_bib26","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934307000356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934307000356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:43:52Z","timestamp":1757580232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934307000356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0002934307000356"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2007.01.005","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Options for Modifying Cardiometabolic Risk Factors","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2007.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}